Year None20222021202020192018 January 11, 2022 Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer January 10, 2022 Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022 January 05, 2022 Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 13 of 13
January 11, 2022 Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
January 10, 2022 Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
January 05, 2022 Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference